XBiotech Inc. (XBIT) Sets 1-Year High on Jan, 28

XBiotech Inc. (NASDAQ:XBIT) Corporate Logo

A one-year high was touched by XBiotech Inc. (NASDAQ:XBIT). Today’s price per share was $6.43. It’s 5.00 % above our $6.75. On Jan, 28 the one-year high was published by Barchart.com. The company has $230.32 million market cap. $11.52 million more could be NASDAQ:XBIT valuation at $6.75 share price.

XBIT is hitting $6.43 during the last trading session, after increased 5.93%.XBiotech Inc. is downtrending after having declined 7.38% since January 28, 2018. XBIT has 229,139 volume or 167.59% up from normal. XBIT underperformed the S&P 500 by 7.38%.

For more XBiotech Inc. (NASDAQ:XBIT) news published recently go to: Nasdaq.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge – Nasdaq” published on December 26, 2018, “Your Daily Pharma Scoop: XBiotech Reports Positive Data, AstraZeneca’s New Approval, Novartis’ Positive MS Trial – Seeking Alpha” on September 17, 2018, “EyePoint Pharmaceuticals and Sesen Bio among healthcare gainers; ZIOPHARM Oncology and Agenus among losers – Seeking Alpha” with a publish date: December 26, 2018, “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” and the last “XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks – GlobeNewswire” with publication date: August 27, 2018.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases.The firm is valued at $230.32 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.Currently it has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *